Literature DB >> 23592187

Optimizing unresectable colorectal liver metastases for surgery--no limits, any benefits?

Tamara M H Gall1, Adam E Frampton, Jonathan Krell, Long R Jiao.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23592187     DOI： 10.1007/s11605-013-2197-2

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN： 1091-255X            Impact factor:   3.452


× No keyword cloud information.
  19 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

Review 2.  Summary outcomes of two-stage resection for advanced colorectal liver metastases.

Authors:  Terence C Chua; Winston Liauw; Francis Chu; David L Morris
Journal:  J Surg Oncol       Date:  2012-05-30       Impact factor: 3.454

3.  Hepatic resection combined with radiofrequency ablation for initially unresectable colorectal liver metastases after effective chemotherapy is a safe procedure with a low incidence of local recurrence.

Authors:  Kosuke Mima; Toru Beppu; Akira Chikamoto; Yuji Miyamoto; Shigeki Nakagawa; Hideyuki Kuroki; Hirohisa Okabe; Hiromitsu Hayashi; Yasuo Sakamoto; Masayuki Watanabe; Ken Kikuchi; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2012-09-01       Impact factor: 3.402

4.  During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma.

Authors:  D Elias; T De Baere; A Roche; J Leclere; P Lasser
Journal:  Br J Surg       Date:  1999-06       Impact factor: 6.939

5.  Risk factors for early recurrence after curative hepatectomy for colorectal liver metastases.

Authors:  Yo-ichi Yamashita; Eisuke Adachi; Yasushi Toh; Kippei Ohgaki; Osamu Ikeda; Eiji Oki; Kazuhito Minami; Yoshihisa Sakaguchi; Eiji Tsujita; Takeshi Okamura
Journal:  Surg Today       Date:  2011-03-23       Impact factor: 2.549

6.  Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.

Authors:  Alfredo Falcone; Sergio Ricci; Isa Brunetti; Elisabetta Pfanner; Giacomo Allegrini; Cecilia Barbara; Lucio Crinò; Giovanni Benedetti; Walter Evangelista; Laura Fanchini; Enrico Cortesi; Vincenzo Picone; Stefano Vitello; Silvana Chiara; Cristina Granetto; Gianfranco Porcile; Luisa Fioretto; Cinzia Orlandini; Michele Andreuccetti; Gianluca Masi
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

7.  Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients.

Authors:  Myrddin Rees; Paris P Tekkis; Fenella K S Welsh; Thomas O'Rourke; Timothy G John
Journal:  Ann Surg       Date:  2008-01       Impact factor: 12.969

8.  Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases.

Authors:  Hassan Z Malik; K Rajendra Prasad; Karim J Halazun; Amir Aldoori; Ahmed Al-Mukhtar; Dhanwant Gomez; J Peter A Lodge; Giles J Toogood
Journal:  Ann Surg       Date:  2007-11       Impact factor: 12.969

9.  The clinical risk score: emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases.

Authors:  Chris D Mann; Matthew S Metcalfe; Lisa N Leopardi; Guy J Maddern
Journal:  Arch Surg       Date:  2004-11

10.  Optimal schedule of adjuvant chemotherapy with S-1 for stage III colon cancer: study protocol for a randomized controlled trial.

Authors:  Kenichi Yoshimura; Keisuke Uehara; Yuichiro Tojima; Satoru Kawai; Yasuji Mokuno; Atsuyuki Maeda; Takanori Kyokane; Satoshi Kobayashi; Yuichiro Yoshioka; Masato Nagino
Journal:  Trials       Date:  2013-01-15       Impact factor: 2.279
View more
  1 in total

Review 1.  Liver-directed therapies in metastatic colorectal cancer.

Authors:  Margaret E Clark; Richard R Smith
Journal:  J Gastrointest Oncol       Date:  2014-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.